Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancer.
Front Med (Lausanne)
; 10: 1338566, 2023.
Article
en En
| MEDLINE
| ID: mdl-38293306
ABSTRACT
The CDK4/6 inhibitor, abemaciclib, is now the standard of care adjuvant therapy for patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) tumors at high risk of recurrence. Real-world usage uncovers emerging side effects that may have been previously unreported in clinical trials. Here, we present the clinical course of a patient who developed a syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury due to abemaciclib use.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Front Med (Lausanne)
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos